Download PDF

1. Company Snapshot

1.a. Company Description

Gritstone bio, Inc., a clinical-stage biotechnology company, engages in developing immunotherapies against multiple cancer types and infectious diseases.Its lead product candidate is GRANITE, a neoantigen-based immunotherapy for the treatment of solid tumors, including metastatic non-small cell lung cancer, as well as gastroesophageal, bladder and microsatellite stable, and colorectal cancers.The company is also developing SLATE, an off-the-shelf immunotherapy candidate for the treatment of common solid tumors comprising metastatic non-small cell lung cancer, colorectal cancer, pancreatic cancer, and shared neoantigen-positive tumors.


In addition, it develops CORAL, a SARS-CoV-2 vaccine platform designed to deliver spike and additional SARS-CoV-2 T cell epitopes for protection and broader immunity against SARS-CoV-2 variants; and a therapeutic vaccine candidate designed to treat and cure human immunodeficiency virus (HIV) infection.It has a strategic collaboration with bluebird bio, Inc.; collaboration agreement with Gilead Sciences, Inc.; and license agreement with Genevant Sciences GmbH.The company was formerly known as Gritstone Oncology, Inc.


and changed its name to Gritstone bio, Inc.in May 2021.Gritstone bio, Inc.


was incorporated in 2015 and is headquartered in Emeryville, California.

Show Full description

1.b. Last Insights on GRTS

Gritstone bio, Inc.'s recent performance was negatively driven by the company's decision to file for Chapter 11 bankruptcy protection. This move was likely a result of the company's financial struggles, as it seeks to preserve value and strengthen its capital structure. The bankruptcy filing has significant implications for the company's operations and future prospects. Additionally, the company's recent announcement of a voluntary petition under Chapter 11 of the United States Bankruptcy Code suggests a significant shift in its business strategy.

1.c. Company Highlights

2. Transcript Summary

Unfortunately this company is not part of our coverage yet. But as part of your subscription plan you can request it by clicking just below and we'll process.

Request Coverage

3. NewsRoom

Card image cap

Gritstone bio Takes Action to Preserve Value and Strengthen Capital Structure

Oct -10

Source: businesswire.com

Card image cap

Penny Stock Gritstone Bio Hires Advisor To Evaluate Options, Analyst Downgrades Stock As Data 'Insufficient To Excite Many Investors'

Oct -01

Source: benzinga.com

Card image cap

Gritstone bio Announces Interim Phase 2 Data for GRANITE Individualized Neoantigen Targeting Immunotherapy in Frontline Metastatic Microsatellite Stable Colorectal Cancer

Sep -30

Source: globenewswire.com

Card image cap

Investors Have The Opportunity To Lead The Gritstone bio, Inc. Securities Fraud Lawsuit With The Schall Law Firm

Aug -15

Source: accesswire.com

Card image cap

Gritstone bio Inc. (GRTS) Reports Q2 Loss, Misses Revenue Estimates

Aug -13

Source: zacks.com

Card image cap

Gritstone bio Reports Second Quarter 2024 Financial Results and Provides Corporate Updates

Aug -13

Source: globenewswire.com

Card image cap

GRITSTONE ALERT: Bragar Eagel & Squire, P.C. is Investigating Gritstone bio, Inc. on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm

Aug -08

Source: globenewswire.com

Card image cap

Investors Are Invited To Take The Lead In The Gritstone Bio Inc Securities Fraud Case With The Schall Law Firm

Aug -07

Source: accesswire.com

4. Business Breakdown

4.a. Revenues by Country

4.b. Revenues by Segment

5. Expected revenues mid-term growth (11.30%)

6. Segments

Vaccine-based Immunotherapy

Expected Growth: 11.3%

Gritstone bio's vaccine-based immunotherapy growth is driven by increasing adoption in oncology, strong clinical trial results, and a growing pipeline of indications. The company's proprietary EDGE platform enables personalized neoantigen-based therapies, addressing a significant unmet need in cancer treatment. Additionally, partnerships with leading pharma companies and a strong balance sheet support the company's rapid expansion.

7. Detailed Products

Personal Neoantigen Cancer Vaccine

A personalized cancer vaccine that uses machine learning and genomics to identify and target specific tumor mutations in each patient.

SLATE-002

A personalized neoantigen-based immunotherapy for the treatment of solid tumors.

GRANITE-001

A personalized neoantigen-based immunotherapy for the treatment of solid tumors, including non-small cell lung cancer and other tumor types.

GRT-C903

A personalized neoantigen-based immunotherapy for the treatment of human papillomavirus (HPV)-associated cancers.

8. Gritstone bio, Inc.'s Porter Forces

Forces Ranking

Threat Of Substitutes

Gritstone bio, Inc. has a moderate threat of substitutes due to the availability of alternative treatments and therapies in the market.

Bargaining Power Of Customers

Gritstone bio, Inc. has a low bargaining power of customers due to the specialized nature of its products and services.

Bargaining Power Of Suppliers

Gritstone bio, Inc. has a moderate bargaining power of suppliers due to the availability of multiple suppliers in the market.

Threat Of New Entrants

Gritstone bio, Inc. has a high threat of new entrants due to the growing demand for biotechnology products and services.

Intensity Of Rivalry

Gritstone bio, Inc. operates in a highly competitive market with several established players, leading to a high intensity of rivalry.

9. SWOT Analysis

Strength

Weaknesses

Opportunities

Threats

10. Capital Structure

10.a. Balance Sheet

10.b. Weighted Average Cost of capital

Value
Debt Weight 47.57%
Debt Cost 3.95%
Equity Weight 52.43%
Equity Cost 7.19%
WACC 5.65%
Leverage 90.74%

11. Quality Control: Gritstone bio, Inc. passed 2 out of 9 key points

12.a Historical Valuation

12.b Price/Earnings Ratio

12.c Margin Valuation

12.d Peers Valuation

Peers Group Analysis

Stock-Card
Inhibikase Therapeutics

A-Score: 3.1/10

Value: 7.0

Growth: 2.4

Quality: 3.1

Yield: 0.0

Momentum: 5.0

Volatility: 1.0

1-Year Total Return ->

View Full Report
Stock-Card
Cardio Diagnostics Holdings

A-Score: 2.9/10

Value: 7.6

Growth: 4.1

Quality: 3.2

Yield: 0.0

Momentum: 2.0

Volatility: 0.7

1-Year Total Return ->

View Full Report
Stock-Card
HCW Biologics

A-Score: 2.8/10

Value: 8.0

Growth: 4.1

Quality: 4.9

Yield: 0.0

Momentum: 0.0

Volatility: 0.0

1-Year Total Return ->

View Full Report
Stock-Card
Sangamo Therapeutics

A-Score: 2.8/10

Value: 7.2

Growth: 3.3

Quality: 4.1

Yield: 0.0

Momentum: 2.0

Volatility: 0.3

1-Year Total Return ->

View Full Report
Stock-Card
Eyenovia

A-Score: 2.6/10

Value: 7.6

Growth: 4.8

Quality: 3.3

Yield: 0.0

Momentum: 0.0

Volatility: 0.0

1-Year Total Return ->

View Full Report
Stock-Card
Gritstone bio

A-Score: 2.6/10

Value: 7.8

Growth: 4.8

Quality: 2.4

Yield: 0.0

Momentum: 0.5

Volatility: 0.0

1-Year Total Return ->

View Full Report

Peers Metrics

12.e Scoring Insights

12.f DCF BETA

Parameters

Short Term Growth

Short term Time

Long-Term Growth

WACC

Target Price

0.03$

Current Price

0.03$

Potential

-0.00%

Expected Cash-Flows